154 related articles for article (PubMed ID: 34519584)
1. EV PD-L1 Contributes to Immunosuppressive CD8
Zhang X; Liu Z; Hou Y; Jiao H; Ren J; Wang G
Technol Cancer Res Treat; 2021; 20():15330338211041264. PubMed ID: 34519584
[TBL] [Abstract][Full Text] [Related]
2. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
[TBL] [Abstract][Full Text] [Related]
3. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
Liu Z; Wen J; Wu C; Hu C; Wang J; Bao Q; Wang H; Wang J; Zhou Q; Wei L; Shen Y; Zhang W
Aging (Albany NY); 2020 Jan; 12(2):1213-1236. PubMed ID: 31981455
[TBL] [Abstract][Full Text] [Related]
6. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
[TBL] [Abstract][Full Text] [Related]
7. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
[TBL] [Abstract][Full Text] [Related]
8. Immune expression in children with Wilms tumor: a pilot study.
Holl EK; Routh JC; Johnston AW; Frazier V; Rice HE; Tracy ET; Nair SK
J Pediatr Urol; 2019 Oct; 15(5):441.e1-441.e8. PubMed ID: 30981637
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies.
Liu J; Peng X; Yang S; Li X; Huang M; Wei S; Zhang S; He G; Zheng H; Fan Q; Yang L; Li H
Cell Commun Signal; 2022 Jan; 20(1):14. PubMed ID: 35090497
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy.
Chen J; Zhong W; Yang M; Hou W; Wang X; Xia K; Yu H; Yang M; Zhou B; Wang B; Huang J; Lin T
Cancer Immunol Immunother; 2021 Sep; 70(9):2657-2668. PubMed ID: 33606065
[TBL] [Abstract][Full Text] [Related]
11. Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer.
Dou X; Hua Y; Chen Z; Chao F; Li M
Clin Exp Immunol; 2022 May; 207(3):307-317. PubMed ID: 35553630
[TBL] [Abstract][Full Text] [Related]
12. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
Nowicki TS; Akiyama R; Huang RR; Shintaku IP; Wang X; Tumeh PC; Singh A; Chmielowski B; Denny C; Federman N; Ribas A
Cancer Immunol Res; 2017 Feb; 5(2):118-126. PubMed ID: 28039162
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes.
Li X; Zhong T; Tang R; Wu C; Xie Y; Liu F; Zhou Z
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32236416
[TBL] [Abstract][Full Text] [Related]
15. Reactive glia promote development of CD103
Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
[TBL] [Abstract][Full Text] [Related]
16. Validation and characterisation of prognostically significant PD-L1
Young RJ; Bressel M; Porceddu S; Cernelc J; Savas P; Liu H; Urban D; Thai AA; Cooper C; Fua T; Neeson P; Rischin D; Solomon B
Oral Oncol; 2020 Feb; 101():104516. PubMed ID: 31838340
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
18. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
19. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
